Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Raw Materials (2017 - 2025)

Catheter Precision has reported Raw Materials over the past 9 years, most recently at $37000.0 for Q4 2025.

  • Quarterly Raw Materials rose 105.56% to $37000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37000.0 through Dec 2025, up 105.56% year-over-year, with the annual reading at $37000.0 for FY2025, 105.56% up from the prior year.
  • Raw Materials was $37000.0 for Q4 2025 at Catheter Precision, up from $23000.0 in the prior quarter.
  • Over five years, Raw Materials peaked at $1.9 million in Q2 2021 and troughed at $18000.0 in Q4 2024.
  • The 5-year median for Raw Materials is $37000.0 (2025), against an average of $605363.6.
  • Year-over-year, Raw Materials crashed 60.87% in 2021 and then soared 105.56% in 2025.
  • A 5-year view of Raw Materials shows it stood at $911000.0 in 2021, then rose by 5.27% to $959000.0 in 2022, then tumbled by 97.18% to $27000.0 in 2023, then tumbled by 33.33% to $18000.0 in 2024, then soared by 105.56% to $37000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Raw Materials are $37000.0 (Q4 2025), $23000.0 (Q3 2025), and $24000.0 (Q2 2025).